Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

Our vision declines as we age leading to the development of various eye conditions such as presbyopia cataracts and glaucoma ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those affected by AMD. Together, TLI and AMDF are dedicated to advancing awareness, ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...